GlassScriptPhysician profile
Nafisa Syed
NPI 1144674383
$3,213.03
in general payments reported to CMS, 2019-2025
27 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $165 · 2023: $830 · 2024: $1,183 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.91 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $443.24 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $341.14 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.45 | 2024-2025 | Jardiance, Ofev |
| Pfizer INC. | $185.61 | 2023-2025 | |
| Amgen INC. | $145.53 | 2024 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $135.44 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $117.36 | 2024 | Wegovy |
| Ardelyx, INC. | $97.22 | 2024-2025 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $91.45 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $76.47 | 2023-2025 | |
| Daiichi Sankyo INC. | $74.90 | 2022-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $73.26 | 2024 | Verquvo |
| Renalytix Ai, INC. | $66.69 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi-Aventis U.S. LLC | $51.94 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.77 | 2023 | Trelegy Ellipta |
| Alkermes, INC. | $39.16 | 2022 | |
| Lilly USA, LLC | $38.12 | 2023-2024 | Emgality, Reyvow, Mounjaro |
| Bardy Diagnostics, INC. | $30.69 | 2022 | |
| Sumitomo Pharma America, INC. | $29.77 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $24.84 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.93 | 2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $23.63 | 2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $20.78 | 2022 | |
| Corcept Therapeutics | $19.21 | 2023 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.02 | 2022 | |
| Amarin Pharma, INC. | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nafisa Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.